Skip to main content

Table 4 Overview of the haematologic parameters measured in the first part of the study at week 16. The ranges mark the 95% confidence intervals

From: Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats

 

Placebo

Everolimus

Placebo + [177Lu]Lu-DOTA-TATE

Everolimus + [177Lu]Lu-DOTA-TATE

RBC (1012/l)

8.33 ± 0.20

9.44 ± 0.45

8.05 ± 0.20

8.84 ± 0.35

Haemoglobin (g/l)

144 ± 3

163 ± 7

138 ± 2

153 ± 4

Haematocrit

0.442 ± 0.007

0.500 ± 0.022

0.431 ± 0.011

0.470 ± 0.016

Reticulocytes (‰)

20.5 ± 3.3

23.6 ± 2.5

21.8 ± 2.2

23.1 ± 3.6

Platelets (109/l)

597 ± 103

544 ± 118

545 ± 111

506 ± 137

WBC (109/l)

4.98 ± 0.86

4.49 ± 0.48

4.94 ± 0.61

4.16 ± 0.63

 Neutrophils

0.81 ± 0.35

1.00 ± 0.30

0.71 ± 0.15

0.89 ± 0.13

 Monocytes

0.12 ± 0.06

0.13 ± 0.07

0.17 ± 0.09

0.15 ± 0.10

 Lymphocytes

4.03 ± 0.65

3.34 ± 0.48

4.03 ± 0.59

3.09 ± 0.57